216 related articles for article (PubMed ID: 36660947)
1. STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.
Rocha SM; Nascimento D; Cardoso AM; Passarinha L; Socorro S; Maia CJ
Mol Med Rep; 2023 Feb; 27(2):. PubMed ID: 36660947
[TBL] [Abstract][Full Text] [Related]
2. STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Rocha SM; Nascimento D; Coelho RS; Cardoso AM; Passarinha LA; Socorro S; Maia CJ
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047621
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis of STEAP1 knockdown in human LNCaP prostate cancer cells.
Rocha SM; Santos FM; Socorro S; Passarinha LA; Maia CJ
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119522. PubMed ID: 37315586
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens.
Gomes IM; Rocha SM; Gaspar C; Alvelos MI; Santos CR; Socorro S; Maia CJ
Med Oncol; 2018 Feb; 35(3):40. PubMed ID: 29464393
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
6. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
7. Six transmembrane epithelial antigen of the prostate 1 is down-regulated by sex hormones in prostate cells.
Gomes IM; Santos CR; Socorro S; Maia CJ
Prostate; 2013 May; 73(6):605-13. PubMed ID: 23060075
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
10. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
11. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Doran MG; Watson PA; Cheal SM; Spratt DE; Wongvipat J; Steckler JM; Carrasquillo JA; Evans MJ; Lewis JS
J Nucl Med; 2014 Dec; 55(12):2045-9. PubMed ID: 25453051
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
13. Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
Shiota M; Machidori A; Abe T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Yokomizo A; Naito S; Eto M
Int J Urol; 2020 Dec; 27(12):1109-1115. PubMed ID: 32929792
[TBL] [Abstract][Full Text] [Related]
14. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
15. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
17. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
18. Bicalutamide dosages used in the treatment of prostate cancer.
Kolvenbag GJ; Nash A
Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
[TBL] [Abstract][Full Text] [Related]
19. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
